Metadherin contributes to the pathogenesis of diffuse large B-cell lymphoma

PLoS ONE

Volumn 7, Issue 6, 2012, Pages

  Ge, Xueling ^a   Lv, Xiao ^a   Feng, Lili ^a   Liu, Xiaoqian ^b   Gao, Junming ^c   Chen, Na ^a   Wang, Xin ^a,d  

^a SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

^b QINGDAO UNIVERSITY   (China)

^c Department of Internal Medicine   (China)

^d SHANDONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; MEMBRANE PROTEIN; MESSENGER RNA; METADHERIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; WNT PROTEIN;

ADULT; APOPTOSIS; ARTICLE; CANCER STAGING; CANCER TISSUE; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; LYMPH NODE HYPERPLASIA; LYMPHOMA CELL LINE; MALE; PATHOGENESIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; UPREGULATION; WESTERN BLOTTING;

AGED; APOPTOSIS; BETA CATENIN; CELL ADHESION MOLECULES; CELL LINE, TUMOR; CELL NUCLEUS; CELL PROLIFERATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; PROTEIN TRANSPORT; RNA, MESSENGER; RNA, SMALL INTERFERING; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION; WNT SIGNALING PATHWAY;

EID: 84863086393     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0039449     Document Type: Article

References (51)

1. The Non-Hodgkin's Lymphoma Classification Project (1997) A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood 89: 3909-3916.
2. Muris JJ, Cillessen SA, Vos W, van Houdt IS, Kummer JA, et al. (2005) Immunohistochemical profiling of caspase signaling pathways predicts clinical response to chemotherapy in primary nodal diffuse large B-cell lymphomas. Blood 105: 2916-2923.
3. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, et al. (2008) IARC Press. Lyon pp. 233-237 WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th Ed.
4. Abid MB, Nasim F, Anwar K, Pervez S, (2005) Diffuse large B cell lymphoma (DLBCL) in Pakistan: an emerging epidemic? Asian Pac J Cancer Prev 6: 531-534.
5. Coiffier B, (2001) Diffuse large cell lymphoma. Curr Opin Oncol 13: 325-234.
6. Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, et al. (1993) Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin lymphoma. N Engl J Med 328: 1002-1006.
7. Sehn LH, Berry B, Chhanabhai M, Fitzgerald C, Gill K, et al. (2007) The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 109: 1857-1861.
8. Coiffier B, (2007) Rituximab therapy in malignant lymphoma. Oncogene 26: 3603-3613.
9. Coiffier B, (2005) State-of-the-art therapeutics: diffuse large B-cell lymphoma. J Clin Oncol 23: 6387-6393.
10. Flowers CR, Sinha R, Vose JM, (2010) Improving Outcomes for Patients with Diffuse Large B-Cell Lymphoma. CA Cancer J Clin 60: 393-408.
11. Su ZZ, Kang DC, Chen Y, Pekarskaya O, Chao W, et al. (2002) Identification and cloning of human astrocyte genes displaying elevated expression after infection with HIV-1 or exposure to HIV-1 envelope glycoprotein by rapid subtraction hybridization, RaSH. Oncogene 21: 3592-3602.
12. Kang DC, Su ZZ, Sarkar D, Emdad L, Volsky DJ, et al. (2005) Cloning and characterization of HIV-1-inducible astrocyte elevated gene-1, AEG-1. Gene 353: 8-15.
13. Brown DM, Ruoslahti E, (2004) Metadherin, a cell surface protein in breast tumors that mediates lung metastasis. Cancer Cell 5: 365-374.
14. Britt DE, Yang DF, Yang DQ, Flanagan D, Callanan H, et al. (2004) Identification of a novel protein, LYRIC, localized to tight junctions of polarized epithelial cells. Exp Cell Res 300: 134-148.
15. Jian-bo X, Hui W, Yu-long H, Chang-hua Z, Long-juan Z, et al. (2011) Astrocyte-elevated gene-1 overexpression is associated with poor prognosis in gastric cancer. Med Oncol 28 (2): 455-462.
16. Yoo BK, Emdad L, Su ZZ, Villanueva A, Chiang DY, et al. (2009) Astrocyte elevated gene-1 regulates hepatocellular carcinoma development and progression. J Clin Invest 119: 465-477.
17. Hu G, Chong RA, Yang Q, Wei Y, Blanco MA, et al. (2009) MTDH activation by 8q22 genomic gain promotes chemoresistance and metastasis of poor-prognosis breast cancer. Cancer Cell 15: 9-20.
18. Kikuno N, Shiina H, Urakami S, Kawamoto K, Hirata H, et al. (2009) Knockdown of astrocyte-elevated gene-1 inhibits prostate cancer progression through upregulation of FOXO3a activity. Oncogene 26: 7647-7655.
19. Yu C, Chen K, Zheng H, Guo X, Jia W, et al. (2009) Overexpression of astrocyte elevated gene-1 (AEG-1) is associated with esophageal squamous cell carcinoma (ESCC) progression and pathogenesis. Carcinogenesis 30: 894-901.
20. Lee SG, Jeon HY, Su ZZ, Richards JE, Vozhilla N, et al. (2009) Astrocyte Elevated Gene-1 contributes to the pathogenesis of neuroblastoma. Oncogene 28: 2476-2484.
21. Liu H, Song X, Liu C, Xie L, Wei L, et al. (2009) Knockdown of astrocyte elevated gene-1 inhibits proliferation and enhancing chemo-sensitivity to cisplatin or doxorubicin in neuroblastoma cells. J Exp Clin Cancer Res 28: 19.
22. Chen W, Ke Z, Shi H, Yang S, Wang L, (2010) Overexpression of AEG-1 in renal cell carcinoma and its correlation with tumor nuclear grade and progression. Neoplasma 57 (6): 522-529.
23. Meng X, Brachova P, Yang S, Xiong Z, Zhang Y, et al. (2011) Knockdown of MTDH sensitizes endometrial cancer cells to cell death induction by death receptor ligand TRAIL and HDAC inhibitor LBH589 co-treatment. PLoS One 6 (6): e20920.
24. Meng F, Luo C, Ma L, Hu Y, Lou G, (2011) Clinical significance of astrocyte elevated gene-1 expression in human epithelial ovarian carcinoma. Int J Gynecol Pathol 30 (2): 145-150.
25. Li C, Li R, Song H, Wang D, Feng T, et al. (2011) Significance of AEG-1 expression in correlation with VEGF, microvessel density and clinicopathological characteristics in triple-negative breast cancer. J Surg Oncol 103 (2): 184-192.
26. Li J, Zhang N, Song LB, Liao WT, Jiang LL, et al. (2008) Astrocyte elevated gene-1 is a novel prognostic marker for breast cancer progression and overall patient survival. Clin Cancer Res 14: 3319-3326.
27. Sarkar D, Emdad L, Lee SG, Yoo BK, Su ZZ, et al. (2009) Astrocyte elevated gene-1: far more than just a gene regulated in astrocytes. Cancer Res 69 (22): 8529-8535.
28. Hu G, Wei Y, Kang Y, (2009) The Multifaceted Role of MTDH/AEG-1 in Cancer Progression. Clin Cancer Res 15 (18): 5615-5620.
29. Emdad L, Sarkar D, Su ZZ, Randolph A, Boukerche H, et al. (2006) Activation of the nuclear factor kappaB pathway by astrocyte elevated gene-1: implications for tumor progression and metastasis. Cancer Res 66: 1509-1516.
30. Sarkar D, Park ES, Emdad L, Lee SG, Su ZZ, et al. (2008) Molecular basis of nuclear factor-kappa B activation by astrocyte elevated gene-1.Cancer Res 68: 1478-1484.
31. Lee SG, Su ZZ, Emdad L, Sarkar D, Fisher PB, (2006) Astrocyte elevated gene-1 (AEG-1) is a target gene of oncogenic Ha-ras requiring phosphatidylinositol 3-kinase and c-Myc. Proc Natl Acad Sci U S A 103: 17390-17395.
32. Lee SG, Su ZZ, Emdad L, Sarkar D, Franke TF, et al. (2007) Astrocyte elevated gene-1 activates cell survival pathways through PI3K-Akt signaling. Oncogene 27: 1114-1121.
33. Moon RT, (2005) Wnt/beta-catenin pathway. Sci STKE 271: cm1.
34. Fodde R, Brabletz T, (2007) Wnt/beta-catenin signaling in cancer stemness and malignant behavior. Curr Opin Cell Biol 19: 150-158.
35. Clevers H, (2006) Wnt/beta-catenin signaling in development and disease. Cell 127: 469-480.
36. Everly DN Jr, Kusano S, Raab-Traub N, (2004) Accumulation of cytoplasmic beta-catenin and nuclear glycogen synthase kinase 3beta in Epstein-Barr virus-infected cells. J Virol 78: 11648-11655.
37. Gelebart P, Anand M, Armanious H, Peters AC, Dien Bard J, et al. (2008) Constitutive activation of the Wnt canonical pathway in mantle cell lymphoma. Blood 112: 5171-5179.
38. Chung R, Peters AC, Armanious H, Anand M, Gelebart P, et al. (2010) Biological and clinical significance of GSK-3beta in mantle cell lymphoma-an immunohistochemical study. Int J Clin Exp Pathol 3: 244-253.
39. Bellei B, Pacchiarotti A, Perez M, Faraggiana T, (2004) Frequent b-catenin overexpression without exon 3 mutation in cutaneous lymphomas. Modern Pathology 17: 1275-1281.
40. Zhang D, O'neil MF, Cunningham MT, Fan F, Olyaee M, et al. (2010) Abnormal Wnt signaling and stem cell activation in reactive lymphoid tissue and low-grade marginal zone lymphoma. Leuk Lymphoma 51: 906-910.
41. Schmidt M, Sievers E, Endo T, Lu D, Carson D, et al. (2009) Targeting Wnt pathway in lymphoma and myeloma cells. Br J Haematol 144: 796-798.
42. Koivula S, Valo E, Raunio A, Hautaniemi S, Leppä S, (2011) Rituximab regulates signaling pathways and alters gene expression associated with cell death and survival in diffuse large B-cell lymphoma. Oncol Rep 25(4): 1183-1190.
43. Ge XL, Lv X, Feng LL, Liu XQ, Wang X, (2012) High expression and nuclear localization of β-catenin in diffuse large B-cell lymphoma. Mol Med Report. In press.
44. Kawahara T, Kawaguchi-Ihara N, Okuhashi Y, Itoh M, Nara N, et al. (2009) Cyclopamine and quercetin suppress the growth of leukemia and lymphoma cells. Anticancer Res 29: 4629-4632.
45. Ge X, Wang X, (2010) Role of Wnt canonical pathway in hematological malignancies. J Hematol Oncol 3: 33.
46. Jaffe ES, Harris NL, Stein H, Vardiman JW, (2001) Pathology and Genetics of Tumors of Hematopoetic and Lymphoid Tissues: World Health Organization Classification of Tumors. Lyon: IARC Press. 351 p.
47. Ding BB, Yu JJ, Yu RY, Mendez LM, Shaknovich R, (2008) Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas. Blood 111 (3): 1515-1523.
48. Amin HM, McDonnell TJ, Medeiros LJ, Rassidakis GZ, Leventaki V, et al. (2003) Characterization of 4 mantle cell lymphoma cell lines. Arch Pathol Lab Med 127: 424-431.
49. Lu YR, Yuan Y, Wang XJ, Wei LL, Chen YN, et al. (2008) The growth inhibitory effect of mesenchymal stem cells on tumor cells in vitro and in vivo. Cancer Biol Ther 7 (2): 245-251.
50. Koopman G, Reutelingsperger CP, Kuijten GA, Keehnen RM, Pals ST, et al. (1994) Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood 84: 1415-1420.
51. Vermes I, Haanen C, Steffens-Nakken H, Reutelingsperger C, (1995) A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled annexin V. J Immunol Methods 184: 39-51.